Investigación y desarrollo
A Colombian company: we use our knowledge of the territory to develop technological solutions, focusing on creating vaccines and therapies against emerging, re-emerging, and tropical diseases prevalent in the region:
Human pipeline
Research
Headquarters
- 820 m²
- 10 Researchers
- Modern Technologies: mRNA
and vectors - Knowledge Generation
- Good Laboratory Practices (GLP)
Ongoing Projects
UniVax
We have developed a universal vaccine against SARS-CoV-2 using a viral vector platform. The vaccine has shown, in preclinical stages, to be safe, immunogenic, and effective against various virus variants. This vaccine is currently undergoing evaluation to initiate clinical trials.
Colombian Ministry of Science, Technology, and Innovation
Vaccines against Zika, chikungunya, and yellow fever are being developed through a partnership with the University of Wisconsin and the Universidad Nacional de Colombia, funded by the Colombian Ministry of Science, Technology, and Innovation. Our goal is to develop and evaluate the vaccines up to the preclinical level, using two technological platforms: viral vector and mRNA.
United States Department of Agriculture (USDA)
In partnership with the University of Wisconsin - Madison, we are currently evaluating our universal COVID-19 vaccine (UniVax) to limit virus transmission in multiple animal species and reduce the risk of transmission to humans. Additionally, we are working on developing a formulation that allows the vaccine to be administered orally or intranasally while maintaining its protective properties.
Equipo de Investigación
En VaxThera tenemos un compromiso de transparencia y calidad en nuestras investigaciones, es
por
esto, que como compañía y equipo de investigación estamos registrados en SCIENTI, la
plataforma del
Ministerio de Ciencia, Tecnología e Innovación, buscando generar conexiones con
otras empresas del
sector así como con instituciones académicas de gran reconocimiento, para
potenciar el ecosistema de
desarrollo en la región.